MicroPort^® CardioFlow is a global leader in innovation within the field of structural heart intervention and cardiac rhythm management. While continuously solidifying its absolute leading position in China's TAVI market and its innovative pipeline advantage across all valvular disease treatments, the company is deeply integrating MicroPort^® CRM's over 60 years of professional expertise, its 12 core product pipelines, and its global portfolio of more than 40 marketed products covering pacemakers, ICDs, and other areas. It is fully committed to building a world-leading integrated platform spanning"structural heart intervention, rhythm management, and heart failure care," thereby constructing a comprehensive device-based management solution for heart failure that covers all etiologies, all stages, and the entire care cycle. By providing physicians and patients with innovative, full-cycle heart failure health management services, the company is dedicated to building a leading enterprise of emerging technologies in cardiac diagnosis and therapy.